Tag Archive for: SAB

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

/in

Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of […]

Read more

Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments

/in

Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief Scientific Officer Janine Schuurman, PhD, Hans Clevers, MD, PhD, and David Sansom, PhD, join the Scientific Advisory Board Appointments strengthen Laigo’s leadership team following its €17m seed financing as the Company advances its SureTACs™ programs towards clinical development UTRECHT, […]

Read more

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)

/in

Lead programme based on a first‑in‑class small‑molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV‑positive head and neck cancer Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027 Progress is complemented with formation of world-class SAB, including leading experts in E3 […]

Read more

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

/in

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug development Appointments strengthen Rewind’s clinical experience as its GPR17 remyelination therapy advances toward clinical trials Leuven, Belgium – 18 June 2025 – Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, […]

Read more

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

/in

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Read more
© Optimum Strategic Communications.